Ambit Biosciences

Ambit Biosciences is a privately held biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory diseases, and other conditions. Ambit's lead compound, AC220, is a novel, potent, highly selective, and orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, currently under clinical investigation for patients with relapsed or refractory AML.